Supplemental Information

Glucocorticoids Acutely Increase Brown Adipose Tissue Activity in Humans, Revealing Species-Specific Differences in UCP-1 Regulation

Lynne E. Ramage, Murat Akyol, Alison M. Fletcher, John Forsythe, Mark Nixon, Roderick N. Carter, Edwin J.R. van Beek, Nicholas M. Morton, Brian R. Walker, and Roland H. Stimson
**Supplemental Information**

*Figure S1 (related to Experimental Procedures) Anatomical location of intra-operative collection of human brown adipose tissue*

A) CT and B) PET/CT fused axial images of the neck from a healthy subject. Intra-operative samples of brown adipose tissue were obtained from the deep supraclavicular region posterior to the lateral thyroid and adjacent to the longus colli muscle, highlighted by the arrow in panel B identifying the adipose tissue with substantial cold-induced $^{18}$fluorodeoxyglucose uptake (blue/yellow areas) in that site. Paired white adipose tissue samples were simultaneously obtained from the superficial adipose tissue in the neck.

A) CT image

B) PET/CT fused image

- trachea
- thyroid
- oesophagus
- clavicle
- sternocleidomastoid
- longus colli
- vertebral body
- 1st rib
- spinal canal

$^{18}$FDG uptake by BAT at site of intra-operative collection
**Figure S2 (related to Figure 4) Human BAT expresses markers of both beige and classic BAT**

Data are mean ± SEM (n=11) for mRNA levels from differentiated human pre-adipocytes cultured from the superficial (WAT, yellow columns) and the deeper (BAT, red columns) depots. The brown adipocytes expressed higher levels of the classic BAT markers Ehf3 and ZIC1 than the white adipocytes. In addition, the brown adipocytes had increased levels of the beige markers TMEM26 and Tbx1 but lower levels of HOXC9. The brown adipocytes tended to have lower levels of the WAT marker leptin than the white adipocytes (p=0.07). *P<0.05, **P<0.01 vs WAT.
Figure S3 (related to Figure 5) Glucocorticoid regulation of human adipocytes

A) Data are mean ± SEM for n=6 paired human white adipocytes cultured for 24 hours in either 0 (blue columns), 100 (red columns) or 1000nM (green columns) cortisol, with basal 0nM normalised to 100%. Cortisol did not alter either basal or isoprenaline-stimulated respiration. B-D) mRNA levels (with 0nM normalised to 100%) from paired B,D) white and C) brown adipocytes (n=8) following 24 hours incubation with cortisol 0, 100 and 1000nM. B) Cortisol did not alter UCP-1 transcript levels in the white adipocytes. mRNA levels of β3-adrenoreceptor (β3-AR) were below the limit of detection in the white adipocytes. Cortisol increased PGC-1α in white adipocytes and C,D) increased classic glucocorticoid (GC)-regulated genes such as hormone sensitive lipase (HSL), adipose triglyceride lipase (ATGL) and Per1 in brown and white adipocytes. *P<0.05, **P<0.01 vs 0nM.
Figure S4 (related to Figure 5) Glucocorticoid regulation of murine adipocytes

A) Data mean ± SEM for mRNA levels from paired primary murine adipocytes from the epididymal (Epi, n=4), inguinal (Ing, n=6) and interscapular brown adipose tissue (iBAT, n=6) depots following 24 hours incubation with the glucocorticoid (GC) cortisol at 0 (blue columns), 100 (red columns) and 1000 nM (green columns). CL316,243 (1μM) was added to inguinal cells (Ing+CL) for 5 days following differentiation to induce browning. B-F) mRNA levels (with 0nM normalised to 100%) from murine B,D,E) inguinal (n=6) and C,F) interscapular brown adipocytes (n=6) following 24 hours incubation with 0, 100 and 1000nM cortisol. G,H) UCP-1 mRNA levels from paired murine G) unstimulated (n=7) and H) CL316,243 treated (n=7) inguinal adipocytes following 4 and 8 hours incubation with 0, 25 (yellow columns), 50 (orange columns), 100 and 1000nM cortisol. Data were analysed by repeated measures ANOVA with post-hoc Bonferroni correction. *P<0.05, **P<0.01 vs 0nM; $P<0.05$ vs 100nM cortisol.
Figure S5 (related to Figure 5) Glucocorticoid regulation of respiration

A,B) Data are mean ± SEM (with basal 0nM normalised to 100%) for paired murine A) inguinal CL316,243 treated (n=7) and B) interscapular brown adipocytes (n=7) incubated for 24 hours with either 0 (blue columns), 100 (red columns) or 1000nM (green columns) cortisol. Cortisol (100nM and 1000nM) decreased isoprenaline-stimulated oxygen consumption in the murine adipocytes. Data were analysed by repeated measures ANOVA with post-hoc Bonferroni testing. *P<0.05 vs 0nM.

C,D) Representative respirometry traces from C) human white (dotted lines) and brown (solid lines) and D) murine inguinal ‘beige’ adipocytes following incubation for 24 hours with either 0 (blue lines), 100 (red lines) or 1000nM (green lines) cortisol. Samples were all analysed in triplicate.
Table S1 (related to Experimental Procedures) Average outdoor environmental temperatures

Data are the mean maximum and minimum outdoor temperatures during the months when the two in vivo human studies were performed. Historical data were obtained from the Met Office Leuchars station which is situated closest to Edinburgh, Scotland, United Kingdom (1).

|                   | Maximum temperature (°C) | Minimum temperature (°C) |
|-------------------|---------------------------|---------------------------|
| **PET/CT study**  |                           |                           |
| March             | 13.3                      | 3.7                       |
| April             | 10.1                      | 2.7                       |
| May               | 12.5                      | 5.3                       |
| June              | 14.5                      | 8.6                       |
| July              | 17.1                      | 10.3                      |
| August            | 18.6                      | 11.3                      |
| September         | 16.2                      | 8.0                       |
| **Thermal imaging study** |                     |                           |
| January           | 6.4                       | 0.3                       |
| February          | 7.8                       | 0.5                       |
| March             | 9.7                       | 2.1                       |
| April             | 13.3                      | 2.7                       |
| May               | 14.0                      | 5.0                       |
**Table S2** (related to Experimental Procedures) **Participants for human in vitro experiments**

| Experiment/Subject number | Operation                  | Underlying diagnosis                  | Age | Sex   | BMI (kg/m²) |
|---------------------------|----------------------------|---------------------------------------|-----|-------|-------------|
| Whole tissue mRNA and histology |                            |                                       |     |       |             |
| 1                         | Parathyroidectomy          | Primary hyperparathyroidism           | 52  | Female | 27.0        |
| 2                         | Parathyroidectomy          | Primary hyperparathyroidism           | 70  | Female | 28.3        |
| 3                         | Parathyroidectomy          | Primary hyperparathyroidism           | 63  | Female | 33.2        |
| 4                         | Thyroid lobectomy          | Papillary carcinoma of thyroid        | 45  | Female | 26.5        |
| 5                         | Thyroid lobectomy          | Hashimoto’s thyroiditis               | 51  | Female | 30.7        |
| 6                         | Parathyroidectomy          | Primary hyperparathyroidism           | 52  | Female | 47.1        |
| 7                         | Thyroid lobectomy          | Follicular adenoma of thyroid         | 48  | Female | 17.6        |
| 8                         | Parathyroidectomy          | Primary hyperparathyroidism           | 54  | Male   | 33.3        |
| 9                         | Thyroid lobectomy          | Benign hyperplastic thyroid nodule    | 39  | Female | 27.7        |
| Additional whole tissue for correlations |                     |                                       |     |       |             |
| 1                         | Thyroidectomy              | Papillary carcinoma of thyroid        | 52  | Female | 39.4        |
| 2                         | Parathyroidectomy          | Primary hyperparathyroidism           | 24  | Male   | 27.7        |
| 3                         | Thyroid lobectomy          | Benign hyperplastic nodule            | 46  | Female | 40.1        |
| 4                         | Thyroidectomy              | Graves’ disease                       | 27  | Female | 30.1        |
| 5                         | Thyroid lobectomy          | Multinodular goitre                   | 37  | Female | 38.5        |
| 6                         | Thyroidectomy              | Graves’ disease                       | 48  | Female | 32.3        |
| 7                         | Thyroid lobectomy          | Follicular adenoma                    | 27  | Female | 23.9        |
| 8                         | Thyroidectomy              | Graves’ disease                       | 57  | Female | 25.8        |
| 9                         | Thyroid lobectomy          | Multinodular goitre                   | 66  | Female | 24.5        |
| 10                        | Thyroidectomy              | Graves’ disease                       | 26  | Female | 20.9        |
| 11                        | Thyroidectomy              | Graves’ disease                       | 36  | Female | 28.2        |
| 12                        | Parathyroidectomy          | Primary hyperparathyroidism           | 62  | Female | 28.4        |
| Cultured adipocytes for mRNA and histology |                     |                                       |     |       |             |
| 1                         | Thyroidectomy              | Graves’ disease                       | 21  | Female | 26.7        |
| 2                         | Thyroidectomy              | Benign hyperplastic nodule            | 39  | Female | 27.8        |
| 3                         | Thyroid lobectomy          | Benign hyperplastic nodule            | 41  | Female | 23.1        |
| 4                         | Parathyroidectomy          | Primary hyperparathyroidism           | 57  | Female | 30.8        |
| 5                         | Parathyroidectomy          | Primary hyperparathyroidism           | 66  | Female | 32.4        |
| 6                         | Thyroidectomy              | Multinodular goitre                   | 49  | Male   | 33.2        |
| 7                         | Parathyroidectomy          | Primary hyperparathyroidism           | 67  | Female | 32.0        |
| 8                         | Thyroid lobectomy          | Benign hyperplastic nodule            | 55  | Female | 29.3        |
| 9                         | Parathyroidectomy          | Primary hyperparathyroidism           | 34  | Female | 31.0        |
| 10                        | Parathyroidectomy          | Primary hyperparathyroidism           | 58  | Female | 44.1        |
| 11                        | Parathyroidectomy          | Primary hyperparathyroidism           | 42  | Male   | 23.1        |
| Respirometry | Operation                        | Pathology                               | Age | Gender | Age |
|-------------|---------------------------------|-----------------------------------------|-----|--------|-----|
| 1           | Thyroid lobectomy                | Toxic thyroid nodule                    | 30  | Male   | 20.2|
| 2           | Thyroid lobectomy                | Follicular thyroid carcinoma            | 35  | Male   | 38.9|
| 3           | Thyroidectomy                    | Graves’ disease                         | 25  | Female | 18.9|
| 4           | Parathyroidectomy                | Primary hyperparathyroidism             | 48  | Female | 28.0|
| 5           | Thyroidectomy                    | Multinodular goitre                     | 41  | Female | 45.7|
| 6           | Thyroidectomy                    | Graves’ disease                         | 31  | Female | 37.8|

| 24 hour incubation with glucocorticoids |
|----------------------------------------|
| Operation                                   | Pathology                               | Age | Gender | Age |
| 1           | Thyroid lobectomy                   | Benign thyroid nodule                   | 41  | Female | 27.5|
| 2           | Parathyroidectomy                   | Hyperparathyroidism                     | 59  | Female | 24.5|
| 3           | Thyroidectomy                       | Papillary thyroid carcinoma             | 52  | Female | 39.4|
| 4           | Thyroid lobectomy                   | Toxic thyroid adenoma                   | 30  | Male   | 20.2|
| 5           | Thyroidectomy                       | Toxic multinodular goitre               | 50  | Female | 22.3|
| 6           | Parathyroidectomy                   | Hyperparathyroidism                     | 39  | Female | 31.7|
| 7           | Parathyroidectomy                   | Hyperparathyroidism                     | 44  | Male   | 37.6|
| 8           | Thyroid lobectomy                   | Follicular adenoma of thyroid           | 43  | Male   | 26.2|

| 24 hour incubation +/- eplerenone |
|----------------------------------|
| Operation                       | Pathology                               | Age | Gender | Age |
| 1           | Thyroid lobectomy                  | Hyperplastic thyroid nodule             | 22  | Female | 28.7|
| 2           | Thyroidectomy                      | Graves’ disease                        | 42  | Female | 38.4|
| 3           | Thyroidectomy                      | Multinodular goitre                    | 51  | Female | 36.1|
| 4           | Thyroid lobectomy                  | Colloid cyst                            | 30  | Female | 25.4|
| 5           | Thyroidectomy                      | Multinodular goitre                    | 57  | Female | 31.1|
| 6           | Parathyroidectomy                  | Hyperparathyroidism                    | 58  | Female | 23.8|
| 7           | Thyroidectomy                      | Papillary thyroid carcinoma            | 31  | Female | 33.8|

| 48 hour incubation with glucocorticoids |
|----------------------------------------|
| Operation                            | Pathology                               | Age | Gender | Age |
| 1           | Thyroid lobectomy                   | Normal thyroid                         | 26  | Female | 25.4|
| 2           | Thyroid lobectomy                   | Multinodular goitre                    | 48  | Female | 32.9|
| 3           | Thyroidectomy                       | Follicular carcinoma of thyroid        | 50  | Female | 26.0|
| 4           | Thyroidectomy                       | Papillary thyroid carcinoma            | 23  | Female | 20.9|
| 5           | Thyroid lobectomy                   | Hurthle cell adenoma                  | 32  | Female | 20.3|
| 6           | Thyroid lobectomy                   | Follicular adenoma of thyroid          | 24  | Male   | 21.6|
| 7           | Thyroidectomy                       | Multinodular goitre                   | 22  | Male   | 35.3|
| 8           | Thyroid lobectomy                   | Follicular adenoma of thyroid          | 45  | Female | 22.5|
| 9           | Thyroidectomy                       | Multinodular goitre                   | 48  | Female | 31.1|
Table S3 (related to Figure 6) Patient characteristics for retrospective analysis of PET/CT scans

Data are mean ± SEM. Anthropometric and biochemical data from patients who attended the Royal Infirmary of Edinburgh to undergo PET/CT scanning as part of their diagnostic pathway. All patients received 400MBq of $^{18}$FDG 60 minutes prior to undergoing PET/CT scanning of their body. Patients were kept in a room at 20-21˚C prior to and following the $^{18}$FDG injection until the PET/CT scan was performed. Data were analysed using the unpaired t test.

|                          | Controls          | Glucocorticoid treated |
|--------------------------|-------------------|------------------------|
| Number of patients       | 120               | 129                    |
| Age (years)              | 64.5 ± 1.4        | 63.5 ± 1.4             |
| Sex (female/ male)       | 66/ 54            | 67/ 62                 |
| Weight (kg)              | 70.2 ± 1.3        | 69.7 ± 1.5             |
| Body mass index (kg/m$^2$) | 25.2 ± 0.4       | 25.0 ± 0.5             |
| Fasting plasma glucose   | 6.0 ± 0.1         | 5.9 ± 0.1              |
| (mmol/L)                 |                   |                        |
Table S4 (related to Experimental Procedures) Primer sequences for qPCR and corresponding probe numbers

All assays were performed using the following primer probe sequences and the Roche probe library, except for β3-adrenoreceptor which was measured using the Taqman assay ID Hs00609046_m1, while hormone sensitive lipase (LIPE) was measured using the SYBR green assay and the forward primer ggaagtgctatcgtctctgg and reverse primer ggcagtcagtggcatctc.

| Gene Name                  | Primer sequences 5’ to 3’ | Roche UPL Probe number |
|----------------------------|----------------------------|------------------------|
| Human samples              |                            |                        |
| *UCP1*                     | F: ctcaccgcagggaaagaag     | 25                     |
|                            | R: ggttgcacatagtactgta     |                        |
| *PRDM16*                   | F: tggtgactgctgacta        | 63                     |
|                            | R: atattatccacgacctctcttt |                        |
| *PPARGC1A* (PGC-1α)       | F: tggagggcagcagggaaag    | 13                     |
|                            | R: ataaacacgcacctctcttt   |                        |
| *DIO2* (de-iodinase type 2)| F: ggaagaggtcctcctctt     | 47                     |
|                            | R: ttttttgggcagcctctcttt  |                        |
| *NR3C1* (glucocorticoid receptor-α) | F: tttttgtgagcagcagggaa  | 11                     |
|                            | R: gcagttgagcagcagtttttt  |                        |
| *NR3C2* (mineralocorticoid receptor) | F: cattttatgagttctctctcttt | 64                     |
|                            | R: ttttttgtgagctcctctcttt |                        |
| *HSD11B1* (11β-HSD1)      | F: caattttgagcagcagttt   | 20                     |
|                            | R: gcagctcagagctcagcagag |                        |
| *HSD11B2* (11β-HSD2)      | F: gtaaagttgagctcagcagcca | 71                     |
|                            | R: cagctcagagctcagcagag  |                        |
| *PPIA* (cyclophilin A)    | F: atgtgctgagcagccaccaat | 48                     |
|                            | R: ttctctactttgagctcacttt |                        |
| *RNA18S5* (18S)           | F: ctctctacttttgagctcacttt | 46                   |
|                            | R: cactctgcaagctcactcttt |                        |
| *MPZL2* (Eva1)            | F: gctcagtagcagtagcagcag | 35                     |
|                            | R: cagctcagagctcagcagag  |                        |
| *EBF3*                    | F: gcctcagagctcagcagcag  | 70                     |
|                            | R: gatctgctcttcagcgagcag |                        |
| *FBXO31*                  | F: ccgctcagagctcagcagcag | 77                     |
|                            | R: gtacactcaaccttcagctgt  |                        |
| *ZIC1*                    | F: atctcagagctcagcagcagcag | 7                   |
|                            | R: gctcagacagcagcagcagcag |                        |
| *CD137*                   | F: cctgtgccttccttccttcctt | 54                     |
|                            | R: gcacagccagcttccttccttc |                        |
| *TMEM26*                  | F: ttcctcagcttcagcttcag  | 64                     |
|                            | R: gctcagcttcagcttcagcttc |                        |
| *TBX1*                    | F: gctctcagcttcagcttcag  | 17                     |
|                            | R: cagctcagcttcagcttcag  |                        |
| *HOXC9*                   | F: gcacagccagcttcagcttcag | 85                     |
|                            | R: gctcagcttcagcttcagcttc |                        |
| *LEP* (leptin)            | F: ttgtgcctcttcagcttcagcttc | 25               |
|                            | R: gtctcagcttcagcttcagcttc |                        |
| *ADIPOQ* (adiponectin)    | F: gtttgctcctcttcagcttcagcttc | 85          |
|                            | R: ttatgctcctcttcagcttcagcttc |                        |
| *EBF2*                    | F: ccgctcagcttccttcagcttc | 11                     |
|                            | R: aaatgctcagcttccttcagcttc |                        |
| *SLC2A1* (GLUT-1)         | F: gtttgctcctcttcagcttcagcttc | 67          |
|                            | R: cagatagcagcttccttcagcttc |                        |
| *SLC2A4* (GLUT-4)         | F: ctrtgcctcttcagcttcagcttc | 67          |
|                            | R: cagatagcagcttccttcagcttc |                        |
| *ZNF516* (zinc finger protein 516) | F: gctcagcttccttcagcttcagcttc | 10          |
|                            | R: gtctcagcttcagcttcagcttc |                        |
| Gene          | Forward Primer  | Reverse Primer  | Length |
|--------------|-----------------|-----------------|--------|
| CEBPB        | F: cgcttaacctgctcatcacc | R: acgaggaggagctggagag | 74     |
| PPARA        | F: gcactggaactgtagcag     | R: ttagaaggcaggacgtct  | 5      |
| CPT1B        | F: gagcagcactcccaac      | R: auctctgtatgtatgtatctgt | 10     |
| PNPLA2 (ATGL) | F: etcecaaatactcagcag | R: ccctggtctccactctcc | 89     |
| PERI         | F: cctctcagctcctccta     | R: eattggatggtgcaggtt   | 87     |
| CYCS (cytochrome C) | F: tgcctgcagcactaaaagag | R: eccectctttaaagctgt | 48     |
| ATP5A1 (F1-ATPase alpha subunit) | F: tgcattttgcataaagactcag | R: gtaacctcagcagctagtc | 61     |
| PPARG        | F: tggaataggctgtaacttgatt | R: ggaggttgtagtttagatggtt | 7      |
| FABP4        | F: ccacaaaaagaaaaagagagag | R: gtggaatgtagcggctttcatt | 31     |
| Murine samples |                  |                 |        |
| RN18S        | F: etcaacagggaaaactcac | R: eacttccgtccactcaact | 77     |
| TBP (TATA box binding protein) | F: gggaagacatcggacgagagag | R: gatgggaactgctggactc | 97     |
| UCP1         | F: ggcctcagctcagctcgcc | R: taatccgctgagattctttg | 34     |
| ADBR3 (β3-adrenoreceptor) | F: cagccactgcctctgtgag | R: eacttcatagcatcaactctcag | 13     |
| PPARGC1A (PGC-1α) | F: gaaagaccaacagcagagagag | R: gataattccagcagctgctt | 29     |
| CEBPB        | F: atcgaatctgctcctcttcct | R: tgcctccgctgagactgctg | 55     |
| PPARA        | F: cctcctctggaacttgacg | R: ccacagagctgactgtgctggt | 5      |
| CPT1B        | F: caaggaatccagcagacagcact | R: ctttcatggaatgttcactcaaca | 64     |
| SLC2A1 (GLUT-1) | F: ggcctactgcacccatg | R: gccaagatgctgcatatgg | 20     |
| SLC2A4 (GLUT-4) | F: gacggacactcactcttgtg | R: gcaagatgagcactctcact | 5      |
| ZF516        | F: ttggcatccatgcttcaccag | R: gtgtgcctgtgagatgtgtagttc | 66     |
| LIPE (hormone sensitive lipase) | F: acegctgcggaggatgtttt | R: ccgcctccagttggaaccc | 3      |
| PNPLA2 (ATGL) | F: gagctcctggtccacac | R: cacactctctattgagaccaa | 89     |
| PERI         | F: gctcgtggttgatgtgacctt | R: tgtttagactgccaggtgtt | 71     |
| CYCS (cytochrome C) | F: aagttgcrtgtgttggctgacc | R: ttagcttgctctctttttc | 104    |
| ATP5A1 (F1-ATPase alpha subunit) | F: getggagacttctagcagagaga | R: ccaagctttaggacatcacc | 31     |
| PPARG        | F: gaaagacccagcagacaactc | R: gggggtgtatggatgtgaaatgtggg | 7      |
| FABP4        | F: ggttggaaatgtagcggccacaaraa | R: tgtatggatgtgagagagacaac | 31     |
Experimental procedures

In vitro studies of BAT activity

Adipose tissue collection in humans

Male and female euthyroid subjects were recruited who were due to undergo elective thyroid or parathyroid surgery in the Royal Infirmary of Edinburgh. During their operation, a small amount of adipose tissue was obtained from the central compartment of the neck, superior to the clavicle and deep to the lateral thyroid lobe either adjacent to the longus colli muscle or to the oesophagus (brown adipose tissue) (Figure S1), and more superficially from the subcutaneous neck tissue (white adipose tissue). This tissue was either immediately frozen, fixed, or the stromal vascular fraction isolated and cultured for the respective experiments. Tissue collections were performed by 2 surgeons.

Adipose tissue collection in mice

Male 129/Ola mice were housed at room temperature (20˚C), 6-8 mice per cage. At 8-9 weeks of age, animals were killed and the interscapular brown adipose tissue, inguinal and epididymal white adipose tissue were immediately collected for isolation of the stromal vascular fraction.

Cell culture studies

Upon collection, adipose tissue was cut into small pieces and digested using 0.2% collagenase type 1 in Krebs-Heinseleit buffer at 37˚C for 45 minutes. Following centrifugation at 600g for 10 minutes at room temperature, the pellet was resuspended and passed through a 100μm filter then subjected to centrifugation at 200g for 5 minutes at room temperature. The pellet was re-suspended in DMEM containing 10% FBS and cultured in 6-well plates. Medium was changed every 2-3 days, and cells were passaged once 80% confluence was achieved. Confluent cells were differentiated in the above
medium with the addition of 1nM tri-iodothyronine, 20nM insulin, 500μM IBMX, 500nM dexamethasone and 125μM indomethacin for 7 days. Cells were then cultured for a further 7 days in DMEM medium containing 10% FBS, 1nM tri-iodothyronine and 20nM insulin prior to experiments. Before experiments testing the effect of varying cortisol concentrations in the medium, cells were deprived of steroids by culture in medium with charcoal stripped serum for 24 hours. Thereafter, depending on the experiments cells were cultured in serum-stripped medium with the addition of varying concentrations of either cortisol, dexamethasone, eplerenone (10μM) or RU38486 (10μM) for incubation periods of between 4 and 48 hours. In the experiments using murine adipocytes, following differentiation half of the wells containing adipocytes from the inguinal depot received 5 days incubation with the β3-agonist CL316,243 (1μM) to induce browning; this was completed prior to commencing incubation with the stripped serum. Experiments were performed after 2-3 passages.

Quantitative real time PCR measurements

Whole adipose tissue (100mg) was homogenised in Qiazol reagent using a rotor-stator homogeniser, and cells were lysed in Qiazol. RNA was extracted using the RNeasy Lipid Kit (Qiagen, Crawley, UK) and cDNA was generated using the Qiagen QuantiTect reverse transcription kit. Real time PCR was performed in triplicate using a Roche Lightcycler 480 (Roche Diagnostics Ltd, Burgess Hill, UK), using gene specific primers (Invitrogen Ltd, Paisley, UK) and fluorescent probes from the Roche Universal Probe Library unless otherwise stated. Primer sequences and probe numbers are described in Table S4. Transcript levels are presented as the ratio of the abundance of the gene of interest: mean of abundance of control genes, with PPIA and 18S used as controls in humans while TBP and 18S were used as control genes in mice.
Histology

Whole adipose tissue was fixed in 10% formalin, paraffin embedded and stained with haematoxylin and eosin prior to viewing on a Zeiss Axioskop. For immunohistochemistry, whole tissue was fixed as above while adipocytes were grown on Superfrost Plus slides and fixed using 10% formalin. Sections were incubated with rabbit anti-human UCP-1 antibody (1:8000 dilution, Sigma U6382) as the primary and goat anti-rabbit (1:200 dilution, Vectastain Elite kit, PK6101) as the secondary antibody according to the avidin-biotin complex method as follows: 1) peroxidase blocking with 3% hydrogen peroxide in methanol for 15 minutes; 2) 20% goat serum for 1 hour to reduce non-specific binding; 3) overnight incubation with primary antibody at 4°C; 4) incubation with secondary antibody for 30 minutes at room temperature; 5) incubation with the Elite ABC reagent for 30 minutes (Vector Labs, Burlingame, CA); 6) incubation with 3,3’-diaminobenzidine for 2 minutes; 7) counterstaining with haematoxylin prior to mounting in Distyrene Plasticizer Xylene.

Respirometry

Paired pre-adipocytes from human WAT and BAT (n=6 subjects) and murine inguinal and interscapular brown depots were differentiated in XF24 V7 (human) or V28 (murine) Cell Culture Microplates (Seahorse Biosciences, Copenhagen, Denmark). White and brown adipocytes were cultured in serum-stripped medium for 24 hours, and then cultured in serum-stripped medium containing 0, 100 or 1000nM cortisol for 24 hours. Cells were then washed and placed in Seahorse XF Assay medium containing 17.5mM glucose and 1mM pyruvate. Oxygen consumption (OCR) and extracellular acidification rates (ECAR) were quantified in triplicate on a Seahorse XFe24 analyser. Measurements were performed of basal and isoprenaline (2μM) stimulated respiration, following subtraction of non-mitochondrial respiration (measured following the addition of rotenone (0.2μM) and antimycin A (2.5μM)). Basal respiration was calculated by taking the mean of 3 cycles (consisting of 2 minutes mixing, 4 minutes waiting, and 2 minutes of measurements) while stimulated
respiration was measured using the results of the 6th cycle following the addition of isoprenaline when the maximum OCR was achieved.

References

1) http://www.metoffice.gov.uk/public/weather/climate-historic/#?tab=climateHistoric